WO2003070261A1 - Pharmacological substance from the plant tribulus terrestris - Google Patents

Pharmacological substance from the plant tribulus terrestris Download PDF

Info

Publication number
WO2003070261A1
WO2003070261A1 PCT/BG2002/000023 BG0200023W WO03070261A1 WO 2003070261 A1 WO2003070261 A1 WO 2003070261A1 BG 0200023 W BG0200023 W BG 0200023W WO 03070261 A1 WO03070261 A1 WO 03070261A1
Authority
WO
WIPO (PCT)
Prior art keywords
plant
bio
pharmacological substance
tribulus terrestris
active substances
Prior art date
Application number
PCT/BG2002/000023
Other languages
French (fr)
Inventor
Blagoy Petrov Alexiev
Original Assignee
Blagoy Petrov Alexiev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blagoy Petrov Alexiev filed Critical Blagoy Petrov Alexiev
Priority to AU2002325689A priority Critical patent/AU2002325689A1/en
Publication of WO2003070261A1 publication Critical patent/WO2003070261A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the invention relates to a pharmacological substance based on biologically active substances obtained from the plant Tribulus terrestris L. to be used as an agent for reduction of blood sugar, improvement of blood circulation and especially blood circulation in veins and capillaries of the limbs of diabetic patients, reduction of bad cholesterol level, increase of good cholesterol concentration, maintenance of cardiovascular and liver activity with an additional prophylactic or healing effect on the immune system and immune resistance.
  • a Chinese medicine composition is known for curing ischemic encephalopathy, hyperlipemia, high blood viscosity, hypertension and diabetes with good therapeutic effect containing Chinese medicinal materials of American ginseng, earthworm, prepared flowery knotweed root, pueraria root, of tribulus terrestris, held cassia seed, spanishneedles, epimedium, ligustrum fruit, aconus root, curcuma tuber and borneol and its preparation method includes the following steps: firstly freezing, drying and grinding earthworm, then grinding borneol, and respectively sieving them; mixing the above- mentioned medicinal materials, decocting them by adding water twice, concentrating the decoction to obtain paste-like extract, cooling adding fine powders of the above mentioned other materials, uniformly stirring them so as to obtain the compound representing the invention.( CN 1275388)
  • a disadvantage of the agent known is that it is difficult to prepare it and that it contains a complicated combination of biologically active substances of vegetal and animal origin the compositions of which are difficult to be controlled when rapid pharmacological effect is to be achieved.
  • the purpose of the invention is to obtain a pharmacological substance representing a combination of bio-active substances of mineral and vegetal origin having a high biological capacity for stimulation and acceleration of blood circulation, limbs nutrition with blood and liver and cardiac activity in a natural way and for increasing diabetic's organism resistant forces.
  • the invention consists in making a pharmacological substance based on biologically active substances obtained from the plant Tribulus Terrestris L. and representing a combination of bio-active trivalent chromium of high glucoside - tolerance factor and a complex of natural products of biological-action steroid saponins obtained from Tribulus Terrestris 1. and consisting of furostanols, spirostanols, sapogenins, sterols, flavonoids and other biologically active substances typical of this plant.
  • the complex of steroid saponins represents 40-80% by weight of the substance and contains furostanols, spirostanols sapogenins, sterols, flavonoids and other biologically active substances typical of this plant in the following rations in % by weight : furostanols from 1 to 35 %, spirostanols from 1 to 40%, sapogenins, from 0.01 to 30 % sterols from 0.01% to 15 %, flavonoids and other bio-active substances from 0.0001 to 15%.
  • the pharmacological substance contains a vegetal bio-active component representing a complex of steroid saponins obtained from the plant Tribulus Terrestris L., a mineral bio-active component and a pharmaceutical or nutritive base in the following ratios in % by weight: vegetal bio-active component representing a complex of steroid saponins obtained from the plant Tribulus Terrestris L. from 1 to 40 % , mineral bio- active component representing a bio-active trivalent chromium from 0.000001 to 10% and a pharmaceutical or a nutritive base from 1 to 55% .
  • the pharmaceutical or nutritive base contains the following components in ratios in % by weight: micro-cristalline cellulose from 0.001 to 60%, dicalcium phosphate from 0.001 to 20%, stearic acid from 0 to 10%, magnesium stearate from 0.0001 to 10%, hydroxypropylic cellulose from 0 to 20 % and highly dispersed silicon dioxide from 0.001 to 10%.
  • the pharmacological substance based on biologically active substances from the plant Tribulus Terrestris L. is obtained by the method where the drug or the extract from the plant Tribulus terrestris L. is subject to treatment at negative temperatures until obtaining a complex of steroid saponins containing furostanols, spirostanols, sapogenins, sterols, flavonoids and other biologically active substances typical of this plant in the following ratios in % by weight: furostanols from 1 to 35 %, spirostanols from 1 to 40%, sapogenins, from 0.01 to 30 % sterols from 0.01% to 15 %, flavonoids and other bio-active substances from 0.0001 to 15%.
  • the pharmacological substance according to the invention is used for treatment or prophylaxis in case of high blood sugar values of diabetics and liver and cardiovascular diseases.
  • the Pharmacological Substance according to the invention is used for treatment or prophylaxis in case of inflammation of varicose veins, kidneys, bladder, prostate gland and as an agent of marked anti-inflammatory effect.
  • the Pharmacological Substance according to the invention is used for increasing good cholesterol concentration and reducing bad cholesterol concentration in blood.
  • the Pharmacological Substance according to the invention is used for treatment or prophylaxis as an active element of a solid medicine or as an addition to food.
  • the Pharmacological Substance according to the invention is simultaneously used for strengthening the immune system, increasing the immune resistance, regulation of the cardiovascular system and liver functioning.
  • the Pharmacological Substance according to the invention is a bio-active complex of bio-active trivalent chromium of high glucoside-tolerance factor and high biological capacity obtained as a result of using special method of its production and of an enriched combination of furostanols, spirostanols, sapogenins, sterols and flavonoids obtained by a specific method of processing of a drug or extract from the leaves, stems and fruit of the plant Tribulus terrestris L. at negative temperatures.
  • the Pharmacological Substance according to the invention has an immediate effect on blood cells metabolism and bad and good cholesterol content in blood plasma while, in the absence of additional influences, having also effect on the correct functioning of blood circulation system, the cardiovascular activity and liver functioning of diabetics.
  • the Pharmacological Substance according to the invention contains a biologically active combination having a complex effect on blood cells metabolism, blood plasma content and cells biochemical composition as a whole, thus influencing at the same time blood circulation, the immune system and the correct metabolism of the whole organism.
  • Solid oral medicine including the Pharmacological Substance according to the invention and representing a tablet and containing the following components: 0.250g vegetal active powder component made from leaves, stems and fruit of the plant Tribulus Terrestris L. and containing a complex of 50-80 % by weight of steroid saponins, the content of the bio-active ingredients in % by weight being as follows:
  • Solid oral medicine including the pharmacological substance according to the invention and representing a gelatin capsule containing the following components: 0.250g vegetal active powder from leaves, stems and fruit of the plant Tribulus Terrestris L., containing a complex of 50-80 % by weight of steroid saponins, the content of bio- active ingredients in % by weight being as follows:
  • the pharmacological substance and especially the complex of steroid saponins of its composition are obtained by processing or extracting at negative temperatures the drug obtained from Tribulus Terrestris L . collected in special conditions until obtaining an active component containing a complex of steroid saponins in a precise ratio in % by weight, this bio-active component being included as the basic vegetal active component of the compositions of the solid oral medicines prepared or of the additions to food.
  • Example 1 The medicine described in Example 1 has been clinically tested in the city of Plovdiv, Bulgaria on patients having increased values of blood sugar and bad cholesterol. This medicine has been administered according to an individual prescription for each case depending on the quantity of blood sugar in a daily dose of 2-6 tablets taken before meal, then blood sugar has been tested in the morning before having meal observing at the same time the parameters of bad and good cholesterol in blood.
  • This medicine can be used by type 1 diabetics taking only tablets and by type 2 diabetics treated with insulin and controlling with difficulty their blood sugar or having a desire to pass to type 1. The dose has been fully assimilated by the organism and the result has become obvious on the very first day. Great tolerance and reliability have been observed, and the following pharmacological effects have been established:
  • Example 2 The addition to food described in Example 2 has been clinically tested in Santa Monica, USA, on diabetics showing high values of blood sugar and bad cholesterol. The addition has been administered according to an individual prescription in each case depending on the content of blood sugar and bad cholesterol in blood in daily doses 2-6 tablets, the following results having been observed:
  • Example 3 The medicine described in Example 3 has been clinically tested in Sofia, Bulgaria, during treatment of diabetics having high blood sugar level values and suffering from an inflammation of the prostate gland.
  • the medicine has been administered according to a individual prescription in each case depending on blood sugar level and the degree of inflammation. Side effects have not been observed, the degree of tolerance by the patients has been very high, and the following results have been observed:
  • Example 4 The addition to food described in Example 4 has been tested in Merylville, USA, on diabetics having high blood sugar and poor blood circulation in limbs. The following results have been observed at the end of the treatment:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention relates to a pharmacological substance based on biologically active substances obtained from the plant Tribulus terrestris L. to be used as an agent reducing blood sugar, improving blood circulation and especially blood circulation in veins and capillaries of the limbs of diabetic patients, reducing bad cholesterol level, increasing good cholesterol concentration, maintaining cardiovascular and liver functioning with an additional prophylactic or healing effect on the immune system and the immune resistance. The pharmacological substance represents a combination of bio-active trivalent chromium and a complex of steroid saponins obtained from the plant Tribulus Terrestris l. and consisting of furostanols, spirostanols, sapogenins, sterols, flavonoids and other biologically active substances typical of this plant.

Description

PHARMACOLOGICAL SUBSTANCE FROM THE PLANT TRIBULUS TERRESTRIS
HELD OF THE INVENTION
The invention relates to a pharmacological substance based on biologically active substances obtained from the plant Tribulus terrestris L. to be used as an agent for reduction of blood sugar, improvement of blood circulation and especially blood circulation in veins and capillaries of the limbs of diabetic patients, reduction of bad cholesterol level, increase of good cholesterol concentration, maintenance of cardiovascular and liver activity with an additional prophylactic or healing effect on the immune system and immune resistance.
PRIOR ART
Multiple agents and preparations for regulation of blood circulation, cardiovascular and liver activity as well as for cholesterol regulation of diabetics are known.
The disadvantages of me agents known lie in the necessity of complex use of different medical preparations in case the objective is to achieve simultaneous effects on different systems and organs of human body.
The use of trivalent chromium of different forms combined with other active substances representing extracts of the plant Ma Huang and coffein as an agent for overweight reduction is also known.
A Chinese medicine composition is known for curing ischemic encephalopathy, hyperlipemia, high blood viscosity, hypertension and diabetes with good therapeutic effect containing Chinese medicinal materials of American ginseng, earthworm, prepared flowery knotweed root, pueraria root, of tribulus terrestris, feted cassia seed, spanishneedles, epimedium, ligustrum fruit, aconus root, curcuma tuber and borneol and its preparation method includes the following steps: firstly freezing, drying and grinding earthworm, then grinding borneol, and respectively sieving them; mixing the above- mentioned medicinal materials, decocting them by adding water twice, concentrating the decoction to obtain paste-like extract, cooling adding fine powders of the above mentioned other materials, uniformly stirring them so as to obtain the compound representing the invention.( CN 1275388)
A disadvantage of the agent known is that it is difficult to prepare it and that it contains a complicated combination of biologically active substances of vegetal and animal origin the compositions of which are difficult to be controlled when rapid pharmacological effect is to be achieved.
SUMMARY OF THE INVENTION
The purpose of the invention is to obtain a pharmacological substance representing a combination of bio-active substances of mineral and vegetal origin having a high biological capacity for stimulation and acceleration of blood circulation, limbs nutrition with blood and liver and cardiac activity in a natural way and for increasing diabetic's organism resistant forces.
The invention consists in making a pharmacological substance based on biologically active substances obtained from the plant Tribulus Terrestris L. and representing a combination of bio-active trivalent chromium of high glucoside - tolerance factor and a complex of natural products of biological-action steroid saponins obtained from Tribulus Terrestris 1. and consisting of furostanols, spirostanols, sapogenins, sterols, flavonoids and other biologically active substances typical of this plant.
The complex of steroid saponins represents 40-80% by weight of the substance and contains furostanols, spirostanols sapogenins, sterols, flavonoids and other biologically active substances typical of this plant in the following rations in % by weight : furostanols from 1 to 35 %, spirostanols from 1 to 40%, sapogenins, from 0.01 to 30 % sterols from 0.01% to 15 %, flavonoids and other bio-active substances from 0.0001 to 15%.
The pharmacological substance contains a vegetal bio-active component representing a complex of steroid saponins obtained from the plant Tribulus Terrestris L., a mineral bio-active component and a pharmaceutical or nutritive base in the following ratios in % by weight: vegetal bio-active component representing a complex of steroid saponins obtained from the plant Tribulus Terrestris L. from 1 to 40 % , mineral bio- active component representing a bio-active trivalent chromium from 0.000001 to 10% and a pharmaceutical or a nutritive base from 1 to 55% .
The pharmaceutical or nutritive base contains the following components in ratios in % by weight: micro-cristalline cellulose from 0.001 to 60%, dicalcium phosphate from 0.001 to 20%, stearic acid from 0 to 10%, magnesium stearate from 0.0001 to 10%, hydroxypropylic cellulose from 0 to 20 % and highly dispersed silicon dioxide from 0.001 to 10%.
The pharmacological substance based on biologically active substances from the plant Tribulus Terrestris L. is obtained by the method where the drug or the extract from the plant Tribulus terrestris L. is subject to treatment at negative temperatures until obtaining a complex of steroid saponins containing furostanols, spirostanols, sapogenins, sterols, flavonoids and other biologically active substances typical of this plant in the following ratios in % by weight: furostanols from 1 to 35 %, spirostanols from 1 to 40%, sapogenins, from 0.01 to 30 % sterols from 0.01% to 15 %, flavonoids and other bio-active substances from 0.0001 to 15%.
The pharmacological substance according to the invention is used for treatment or prophylaxis in case of high blood sugar values of diabetics and liver and cardiovascular diseases.
The Pharmacological Substance according to the invention is used for treatment or prophylaxis in case of inflammation of varicose veins, kidneys, bladder, prostate gland and as an agent of marked anti-inflammatory effect.
The Pharmacological Substance according to the invention is used for increasing good cholesterol concentration and reducing bad cholesterol concentration in blood.
The Pharmacological Substance according to the invention is used for treatment or prophylaxis as an active element of a solid medicine or as an addition to food.
The Pharmacological Substance according to the invention is simultaneously used for strengthening the immune system, increasing the immune resistance, regulation of the cardiovascular system and liver functioning.
The advantages of the invention are:
The Pharmacological Substance according to the invention is a bio-active complex of bio-active trivalent chromium of high glucoside-tolerance factor and high biological capacity obtained as a result of using special method of its production and of an enriched combination of furostanols, spirostanols, sapogenins, sterols and flavonoids obtained by a specific method of processing of a drug or extract from the leaves, stems and fruit of the plant Tribulus terrestris L. at negative temperatures.
The Pharmacological Substance according to the invention has an immediate effect on blood cells metabolism and bad and good cholesterol content in blood plasma while, in the absence of additional influences, having also effect on the correct functioning of blood circulation system, the cardiovascular activity and liver functioning of diabetics.
The Pharmacological Substance according to the invention contains a biologically active combination having a complex effect on blood cells metabolism, blood plasma content and cells biochemical composition as a whole, thus influencing at the same time blood circulation, the immune system and the correct metabolism of the whole organism.
The oral forms of the medicines and the additions to food made on the basis of the Pharmacological Substance according to the invention have a rapid action and are harmless in case of prolonged use in clinical conditions or at home. They are well tolerated by the organism, and they have no negative side effects. EXAMPLES
The following examples are illustrative of the invention but not limiting it:
EXAMPLE 1
Solid oral medicine including the Pharmacological Substance according to the invention and representing a tablet and containing the following components: 0.250g vegetal active powder component made from leaves, stems and fruit of the plant Tribulus Terrestris L. and containing a complex of 50-80 % by weight of steroid saponins, the content of the bio-active ingredients in % by weight being as follows:
- furostanols from 20 to 30 %
- spirostanols from 30 to 35%
- sapogenins from 17 to 25%
- sterols from 0.01 to 10%
- flavonoids and other active substances from 0.1 to 10% Mineral active component:
- bio-active trivalent chromium - 0.0002g Pharmaceutical base containing
- monocrystalline cellulose - 0.300g
- dicalcium phosphate - O.lOOg
- stearic acid - 0.027g
- magnesium stearate - 0.025g
- hydroxypropylic cellulose - 0.020g
- highly dispersed silicon dioxide - 0.00 lg
EXAMPLE 2
Addition to food including the Pharmacological Substance according to the invention and representing a tablet and containing the following components: 0.250g vegetal active component representing a total extract of leaves, stems and fruit of the plant Tribulus Terrestris L., containing a complex of 50-60 % by weight of steroid saponins, the content of the bio-active ingredients in % by weight being as follows:
- furostanols from 20 to 25 %
- spirostanols from 32 to 35%
- sapogenins from 15 to 20% - sterols from 0.1 to 7%
- flavonoids and other active substances from 0.1 to 12% Mineral active component:
-bio-active trivalent chromium - 0.0002g Nutritive base containing
- monocrystalline cellulose - 0.300g - dicalcium phosphate - O.lOOg
- stearic acid - 0.027g
- magnesium stearate - 0.025g
- hydroxypropylic cellulose - 0.020g
- highly dispersed silicon dioxide - O.OOlg
EXAMPLE 3
Solid oral medicine including the pharmacological substance according to the invention and representing a gelatin capsule containing the following components: 0.250g vegetal active powder from leaves, stems and fruit of the plant Tribulus Terrestris L., containing a complex of 50-80 % by weight of steroid saponins, the content of bio- active ingredients in % by weight being as follows:
- furostanols from 20 to 30 %
- spirostanols from 30 to 35%
- sapogenins from 17 to 25%
- sterols from 0.1 to 10%
- flavonoids and other active substances from 0.1 to 10% Mineral active component:
-bio-active trivalent chromium - 0.0002g Pharmaceutical base containing
- monocrystalline cellulose - 0.350g
- dicalcium phosphate - O.lOOg
- magnesium stearate - 0.025g
- highly dispersed silicon dioxide - O.OOlg
EXAMPLE 4
Addition to food including the pharmacological substance according to the invention and representing a solid gelatin capsule containing the following components: 0.250g vegetal active component representing a total extract of leaves, stems and fruit of the plant Tribulus Terrestris L., containing a complex of 50-60 % by weight of steroid saponins, the content of the bio-active ingredients in % by weight being as follows:
- furostanols from 20 to 25 %
- spirostanols from 32 to 35%
- sapogenins from 15 to 20%
- sterols from 0.1 to 7%
- flavonoids and other active substances from 0.1 to 12% Mineral active component:
- bio-active trivalent chromium - 0.0002g Nutritive base containing - monocrystalline cellulose - 0.350g
- dicalcium phosphate - O.lOOg
- magnesium stearate - 0.025g
- highly dispersed silicon dioxide - O.OOlg
In another version of the invention the pharmacological substance and especially the complex of steroid saponins of its composition are obtained by processing or extracting at negative temperatures the drug obtained from Tribulus Terrestris L . collected in special conditions until obtaining an active component containing a complex of steroid saponins in a precise ratio in % by weight, this bio-active component being included as the basic vegetal active component of the compositions of the solid oral medicines prepared or of the additions to food.
USE OF THE INVENTION
The medicine described in Example 1 has been clinically tested in the city of Plovdiv, Bulgaria on patients having increased values of blood sugar and bad cholesterol. This medicine has been administered according to an individual prescription for each case depending on the quantity of blood sugar in a daily dose of 2-6 tablets taken before meal, then blood sugar has been tested in the morning before having meal observing at the same time the parameters of bad and good cholesterol in blood. This medicine can be used by type 1 diabetics taking only tablets and by type 2 diabetics treated with insulin and controlling with difficulty their blood sugar or having a desire to pass to type 1. The dose has been fully assimilated by the organism and the result has become obvious on the very first day. Great tolerance and reliability have been observed, and the following pharmacological effects have been established:
- high blood sugar level reduction by 30%;
- bad cholesterol level reduction to the limit of its normal content as in healthy persons blood;
- improvement of blood circulation in limbs capillaries and veins by 35%.
The addition to food described in Example 2 has been clinically tested in Santa Monica, USA, on diabetics showing high values of blood sugar and bad cholesterol. The addition has been administered according to an individual prescription in each case depending on the content of blood sugar and bad cholesterol in blood in daily doses 2-6 tablets, the following results having been observed:
- high blood sugar level reduction by 50%;
- improvement of cardiac and liver activity in 32% of the cases;
- bad cholesterol level reduction to the limit of its normal content as in case of healthy persons blood; - good cholesterol level increase to the limit of its normal value as in healthy persons
- anti- inflammatory effect on inflamed varicose veins, kidneys, bladder, prostate gland in 38% of the cases.
The medicine described in Example 3 has been clinically tested in Sofia, Bulgaria, during treatment of diabetics having high blood sugar level values and suffering from an inflammation of the prostate gland. The medicine has been administered according to a individual prescription in each case depending on blood sugar level and the degree of inflammation. Side effects have not been observed, the degree of tolerance by the patients has been very high, and the following results have been observed:
- high blood sugar level reduction by 29%;
- dying away of prostate gland inflammation by 43%.
The addition to food described in Example 4 has been tested in Merylville, USA, on diabetics having high blood sugar and poor blood circulation in limbs. The following results have been observed at the end of the treatment:
- high blood sugar level reduction by 44%;
- improvement of blood circulation in limbs by 67%; improvement and strengthening of the immune system and the immune resistance by 36%.

Claims

PATENT CLAIMS
1. Pharmacological substance based on biologically active substances obtained from the plant Tribulus Terrestris L. characterized by that it is a combination of bio-active trivalent chromium and a complex of steroid saponins obtained from the plant Tribulus Terrestris L. and consisting of furostanols, spirostanols, sapogenins, sterols, flavonoids and other biologically active substances typical of this plant.
2. Pharmacological substance according to Claim 1 above, characterized by that its complex of steroid saponins represents 40-80% by weight of the substance and contains furostanols, spirostanols sapogenins, sterols, flavonoids and other biologically active substances typical of this plant in the following ratios in % by weight :
- furostanols from 1 to 35 %,
- spirostanols from 1 to 40%,
- sapogenins, from 0.01 to 30 %
- sterols from 0.01% to 15 %,
- flavonoids and other bio-active substances from 0.0001 to 15%.
3. Pharmacological substance according to Claim 1 and 2 above, characterized by that it contains a vegetal bio-active component representing a complex of steroid saponins obtained from the plant Tribulus Terrestris L., a mineral bio-active component and a pharmaceutical or nutritive base in the following ratios in % by weight:
- vegetal bio-active component representing a complex of steroid saponins obtained from the plant Tribulus Terrestris L. from 1 to 40 %
- mineral bio-active component representing a bio-active trivalent chromium from 0.000001 to 10%
- pharmaceutical or a nutritive base from 1 to 55%.
4. Pharmacological substance according to Claim 1,2 and 3 above, characterized by that its pharmaceutical or nutritive base contains the following components in ratios in % by weight:
- micro-cristalline cellulose from 0.001 to 60%,
- dicalcium phosphate from 0.001 to 20%,
- stearic acid from 0 to 10%,
- magnesium stearate from 0.0001 to 10%,
- hydroxypropylic cellulose from 0 to 20 %
- highly dispersed silicon dioxide from 0.001 to 10%.
5. The method of obtaining the Pharmacological Substance based on biologically active substances obtained from the plant Tribulus Terrestris L. , characterized by processing drug or the extract from the plant Tribulus terrestris L. at negative temperatures until obtaining a complex of steroid saponins containing furostanols, spirostanols, sapogenins, sterols, flavonoids and other biologically active substances typical of this plant in the following ratios in % by weight:
- furostanols from 1 to 35 %,
- spirostanols from 1 to 40%,
- sapogenins, from 0.01 to 30 %
- sterols from 0.01% to 15 %,
- flavonoids and other bio-active substances from 0.0001 to 15%.
6. Use of the Pharmacological Substance according to Claim 1 to 4 above for treatment or prophylaxis in case of high blood sugar values of diabetics and liver and cardiovascular diseases.
7. Use of the Pharmacological Substance according to Claim 1 to 4 above for treatment in case of inflammation of varicose veins, kidneys, bladder, prostate gland and as an agent of marked anti-inflammatory effect.
8. Use of the Pharmacological Substance according to Claim 1 to 4 above for increasing good cholesterol concentration and reducing bad cholesterol concentration in blood.
9. Pharmacological Substance according to Claim 1 to 4 above used for strengthening the immune system, increasing the immune resistance, regulation of the cardiovascular system and liver functioning.
PCT/BG2002/000023 2002-02-25 2002-09-19 Pharmacological substance from the plant tribulus terrestris WO2003070261A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002325689A AU2002325689A1 (en) 2002-02-25 2002-09-19 Pharmacological substance from the plant tribulus terrestris

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BG106434A BG106434A (en) 2002-02-25 2002-02-25 Pharmacological subtance
BG106434 2002-02-25

Publications (1)

Publication Number Publication Date
WO2003070261A1 true WO2003070261A1 (en) 2003-08-28

Family

ID=27739967

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BG2002/000023 WO2003070261A1 (en) 2002-02-25 2002-09-19 Pharmacological substance from the plant tribulus terrestris

Country Status (3)

Country Link
AU (1) AU2002325689A1 (en)
BG (1) BG106434A (en)
WO (1) WO2003070261A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007026201A1 (en) * 2005-09-01 2007-03-08 Council Of Scientific And Industrial Research A pharmaceutical composition useful for the treatment of prostate cancer
US7906493B2 (en) 2003-12-22 2011-03-15 Btg International Limited Core 2 GlcNAc-T inhibitors
US7998943B2 (en) 2005-07-06 2011-08-16 Btg International Limited Core 2 GlcNAc-T inhibitors III
US8197794B2 (en) 2003-12-22 2012-06-12 Ms Therapeutics Limited Core 2 GlcNAc-T inhibitors
US8609633B2 (en) 2005-07-06 2013-12-17 Ms Therapeutics Limited Core 2 GlcNAc-T inhibitors
US20140205687A1 (en) * 2011-08-23 2014-07-24 Mustafa Tekin Tribulus terrestris, avena sativa and panax ginseng extract combination
JP2017192312A (en) * 2016-04-18 2017-10-26 キッコーマン株式会社 Food and drink comprising tomatoside a and used for inhibiting increased blood glucose

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04169534A (en) * 1990-10-30 1992-06-17 Morishita Jintan Kk Therapeutic agent for prostatic hypertrophy
WO2001011971A1 (en) * 1999-08-13 2001-02-22 ALEXIS Brian Natural, anti-bacterial, anti-inflammation, anti-virus, anti-herpes cream

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04169534A (en) * 1990-10-30 1992-06-17 Morishita Jintan Kk Therapeutic agent for prostatic hypertrophy
WO2001011971A1 (en) * 1999-08-13 2001-02-22 ALEXIS Brian Natural, anti-bacterial, anti-inflammation, anti-virus, anti-herpes cream

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOLLETTINO CHIMICO FARMACEUTICO. ITALY DEC 1998, vol. 137, no. 11, December 1998 (1998-12-01), pages 473 - 475, ISSN: 0006-6648 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; December 1998 (1998-12-01), ARCASOY H B ET AL: "Effect of Tribulus terrestris L. saponin mixture on some smooth muscle preparations: a preliminary study.", XP002243196, Database accession no. NLM10077881 *
KRCIK J A: "Performance-enhancing substances: what athletes are using.", CLEVELAND CLINIC JOURNAL OF MEDICINE. UNITED STATES APR 2001, vol. 68, no. 4, April 2001 (2001-04-01), pages 283, 288 - 289, 295 - 297 passim, XP008017669, ISSN: 0891-1150 *
PATENT ABSTRACTS OF JAPAN vol. 016, no. 470 (C - 0990) 30 September 1992 (1992-09-30) *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906493B2 (en) 2003-12-22 2011-03-15 Btg International Limited Core 2 GlcNAc-T inhibitors
US8197794B2 (en) 2003-12-22 2012-06-12 Ms Therapeutics Limited Core 2 GlcNAc-T inhibitors
US7998943B2 (en) 2005-07-06 2011-08-16 Btg International Limited Core 2 GlcNAc-T inhibitors III
US8609633B2 (en) 2005-07-06 2013-12-17 Ms Therapeutics Limited Core 2 GlcNAc-T inhibitors
WO2007026201A1 (en) * 2005-09-01 2007-03-08 Council Of Scientific And Industrial Research A pharmaceutical composition useful for the treatment of prostate cancer
GB2443588A (en) * 2005-09-01 2008-05-07 Council Scient Ind Res A pharmaceutcal composition useful for the treatment of prostate cancer
GB2443588B (en) * 2005-09-01 2010-04-21 Council Scient Ind Res A pharmaceutical composition useful for the treatment of prostate cancer
US20140205687A1 (en) * 2011-08-23 2014-07-24 Mustafa Tekin Tribulus terrestris, avena sativa and panax ginseng extract combination
JP2017192312A (en) * 2016-04-18 2017-10-26 キッコーマン株式会社 Food and drink comprising tomatoside a and used for inhibiting increased blood glucose

Also Published As

Publication number Publication date
BG106434A (en) 2003-09-30
AU2002325689A1 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
US7989005B2 (en) Corosolic acid formulation and its application for weight-loss management and blood sugar balance
JP2006515615A (en) Herbal composition for prostate symptoms
CN101579120A (en) Nutritional food with weight-losing function and preparation method thereof
CN101253903B (en) Health food with fat-reducing function and its preparation
US20050163874A1 (en) Data analysis method
CN108578544A (en) A kind of Chinese medicine composition and the preparation method and application thereof with blood sugar reducing function
JP6145552B1 (en) Fatty liver treatment composition
WO2003070261A1 (en) Pharmacological substance from the plant tribulus terrestris
JP2009013083A (en) Orally administerable composition
CN103479754A (en) Hypotensive drug and preparation method thereof
CN106562165A (en) Slimming type blended fruit-vegetable juice drink and preparation method thereof
CN103721187A (en) Blood-circulation-promoting and blood-fat-reducing pill for treating hyperlipemia and preparation method of pill
CN103181557A (en) Nutritious food with slimming function and preparation method thereof
KR20020004686A (en) Healty food composition for obesity control
CN108904596B (en) Composition with memory improving effect
CN103933282B (en) A kind of Chinese medicinal capsule for treating diabetes
Sharma et al. Adaptogens: New Age Healing Gems for Physical Wellbeing
CN101579121A (en) Nutritional food with hpyerglycemic function and preparation method thereof
CN105533596A (en) Propolis, radix salviae miltiorrhizae and ginkgo leaf capsules and preparation method thereof
JPH0733676A (en) Composition for lowering blood suger value
CN105288501A (en) Traditional Chinese medicine composition containing folium artemisiae argyi and treating obesity
CN110840996A (en) Traditional Chinese medicine formula, method, preparation and application for treating qi-yin deficiency metabolic syndrome
Dworschák et al. Medical activities of Aesculus hippocastaneum (horse-chestnut) saponins
CN100531740C (en) Health care products for auxiliary treatment of diseases of cardio-cerebral blood vessels
CN109602732A (en) A kind of composition and the preparation method and application thereof improving osteoporosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10505743

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP